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Abstract BG-12, an immunomodulatory agent, reduces
frequency of new gadolinium-enhancing (Gd?) lesions in
relapsing multiple sclerosis (MS). This study reports the
effect of 240 mg BG-12 orally three times daily (tid)
for 24 weeks on the evolution of new Gd? lesions to
T1-hypointense lesions. Brain magnetic resonance imag-
ing (MRI) scans from patients in placebo and 240 mg
BG-12 tid arms of a phase 2b study were examined
retrospectively. Included patients had at least one new
Gd? lesion from weeks 4 to 12. Week 24 scans were
analyzed for number and proportion of new Gd? lesions
that evolved to T1-hypointense lesions. Eighteen patients
receiving BG-12 and 38 patients receiving placebo were
included in the analysis. The analysis tracked 147 new
Gd? lesions in patients from the BG-12 group and 221
Gd? lesions in patients from the placebo group. The
percentage of Gd? lesions that evolved to T1-hypointense
lesions was 34% lower with BG-12 treatment versus pla-
cebo (29%, BG-12; 44%, placebo; odds ratio 0.51; 95%
confidence interval 0.43, 0.61; p \ 0.0001). In addition to
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reducing frequency of new Gd? lesions, BG-12 signifi-
cantly reduced probability of their evolution to T1-hypo-
intense lesions in patients with MS compared with
placebo.
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Introduction
BG-12 is an oral formulation of dimethyl fumarate (DMF)
currently in clinical development for relapsing forms of
multiple sclerosis (MS). Preclinical studies using in vitro
cell cultures and in vivo experimental autoimmune
encephalomyelitis models have demonstrated anti-inflam-
matory and neuroprotective effects of DMF and its pri-
mary metabolite, monomethyl fumarate [1, 2]. DMF and
monomethyl fumarate activate the nuclear factor ery-
throid-2-related factor (Nrf2) transcriptional pathway [3],
which is central to oxidative and metabolic stress
response, essential for immune homeostasis, and impli-
cated as a regulator of myelin maintenance in the central
nervous system [4–7].
In a double-blind, dose-ranging, phase 2b study of BG-
12 in patients with relapsing MS, 257 patients were ran-
domized to receive BG-12 at rates of 120 mg once daily
(qd), 120 mg three times daily (tid; 360 mg/day), 240 mg
tid (720 mg/day), or placebo for 24 weeks during an
initial placebo-controlled treatment period [8]. Treatment
with 240 mg BG-12 tid resulted in a 69% reduction in
total mean number of new gadolinium-enhancing (Gd?)
lesions on MRI scans from weeks 12 to 24 compared with
placebo (4.5, BG-12; 1.4, placebo; p \ 0.001). BG-12 at
240 mg tid also reduced the number of new/enlarging
T2-hyperintense lesions by 48% (p \ 0.001) and new
T1-hypointense lesions by 53% (p = 0.014) compared
with placebo. This greater effect on T1-hypointense
lesions versus T2-hyperintense lesions is unusual because
disease-modifying therapies typically have a greater
impact on T2-hyperintense lesions; thus, further investi-
gation was warranted.
Some, but not all, Gd? lesions evolve to persistent
T1-hypointense lesions seen on T1-weighted spin echo
images [9]. The presence of persistent nonenhancing
T1-hypointense lesions on brain magnetic resonance
imaging (MRI) scans of patients with MS is considered a
putative marker for myelin and axonal damage [10]. In
this retrospective analysis of the phase 2b study, we
investigate whether BG-12 affected the evolution of new
Gd? lesions to persistent T1-hypointense lesions in
patients with relapsing MS.
Patients and methods
Patients and study design
The 240 mg BG-12 tid group was the only BG-12 treat-
ment group included in this retrospective analysis because
it was the BG-12 study arm that showed significant and
greatest reduction in Gd? lesions, T2-hyperintense lesions,
and T1-hypointense lesions compared with placebo. Full
study methods have been published elsewhere [8]. Briefly,
this double-blind, parallel-group, dose-ranging phase 2b
study of BG-12 enrolled 257 patients from 43 centers in the
Czech Republic, Germany, Hungary, the Netherlands,
Poland, Russia, Sweden, Switzerland, Turkey, and the
United Kingdom. During an initial placebo-controlled
treatment period, patients were equally randomized to
receive BG-12 at 120 mg qd, 120 mg tid, 240 mg tid, or
placebo for 24 weeks. Key inclusion criteria were patient
age between 18 and 55 years (inclusive); a diagnosis of
relapsing-remitting MS according to the McDonald criteria
(nos. 1–4) [11]; a baseline Expanded Disability Status
Scale score between 0.0 and 5.0 (inclusive) [12]; and at
least one relapse within 12 months before randomization
and a brain MRI consistent with MS, or Gd? lesions on
MRI performed within 6 weeks of randomization. Patients
were excluded if they received mitoxantrone or cyclo-
phosphamide within 1 year; cyclosporine, azathioprine,
methotrexate, natalizumab, intravenous immunoglobulin,
plasmapheresis, or other investigational drugs within
6 months; glatiramer acetate or interferon beta within
3 months; or corticosteroids (oral or intravenous), 4-ami-
nopyridine, or related products within 30 days of
randomization.
Standard protocol approvals and registrations
The study protocol was approved by independent ethics
committees, and the study was conducted in accordance
with the Declaration of Helsinki, International Conference
of Harmonisation and Good Clinical Practice guidelines,
and local regulations. Informed consent was provided by
all patients enrolled in the study. The study was registered
on ClinicalTrials.gov (identifier NCT00168701).
MRI acquisition protocol and analysis
Brain MRI scans were obtained at baseline and weeks 4, 8,
12, 16, 20, and 24 using a system operating at 1.0 or 1.5
tesla. A dual-echo fast spin echo sequence (repetition
time = 2,500–3,300 ms; short echo time = 10–40 ms;
long echo time = 80–100 ms) was used to obtain proton
density and T2-weighted images. A conventional spin echo
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sequence (repetition time = 500–700 ms; echo time =
10–20 ms) was applied for obtaining T1-weighted images
(before and after the injection of 0.1 mmol/kg gadolinium
contrast medium) in the corresponding spatial location to
the fast spin echo scans. For all MRI sequences, 46 con-
tiguous 3 mm thick axial slices were acquired using a field
view of 250 mm, a reconstructed image matrix of 256 9
256, and an in-plane spatial resolution of 0.97 9 0.97 mm.
MRI analysis
After completion of the clinical study, a retrospective anal-
ysis was performed using MRI scans obtained from patients
assigned to the 240 mg BG-12 tid and placebo groups in the
phase 2b study. Examination of all scans was performed by
personnel (DGM, KS, TAY) blinded to the patients’ treat-
ment group assignment and clinical details. Lesions were
analyzed by visual inspection of all scans using electronic
data where available and hard copy images where satisfac-
tory electronic data were not available. All new Gd? lesions
were identified on scans from weeks 4, 8, and 12. To confirm
that the new Gd? lesions also were de novo T2 lesions, the
prior MRI scan was reviewed. Regions of new gadolinium
enhancement in pre-existing T2 lesions were not included in
the analysis because there already may have been tissue
damage, which would influence the likelihood of subsequent
T1 hypointensity in these regions. Gd? lesions were clas-
sified as large ([5 mm) or small (B5 mm) based on mea-
surement of their largest diameter. This cutoff criterion
([5 mm and B5 mm) was chosen for this analysis because it
was used in similar analyses for other MS therapeutics [13,
14]. The status of the new Gd? lesions was evaluated on
postcontrast T1-weighted scans obtained at week 24 and
reported as still Gd? or no longer enhancing. Nonenhancing
lesions were further classified as T1-isointense lesions or T1-
hypointense lesions relative to the surrounding normal-
appearing white matter. The size of the nonenhancing
lesions ([5 mm or B5 mm) also was recorded.
Statistical analysis
Patients in the placebo and 240 mg BG-12 tid arms who
had at least one Gd? lesion from weeks 4 to 12 were
included in the analysis. For each patient, the following
were calculated: cumulative number of new Gd? lesions
on MRI scans from weeks 4 to 12, cumulative number of
T1-hypointense lesions that formed from the Gd? lesions
at week 24, and proportion of Gd? lesions from weeks 4 to
12 that evolved to T1-hypointense lesions at week 24. For
each treatment group, the following were calculated: total
number of new Gd? lesions from weeks 4 to 12, total
number and proportion of Gd? lesions that evolved to
T1-hypointense lesions at week 24, and number and
proportion of large ([5 mm) and small (B5 mm) Gd?
lesions and T1-hypointense lesions. Summary statistics
were used to describe these data.
At the lesion level, a logistic regression model based on
generalized estimating equations which take into account
within-patient correlation of lesions, was used to analyze
and compare the probability of evolution from a new Gd?
lesion to a T1-hypointense lesion between the BG-12 and
placebo groups. For the primary analysis, the model was
adjusted for baseline number of Gd? lesions. In additional
analyses, the model was adjusted for baseline number of
Gd? lesions, years since disease onset, and relapses in the
previous 3 years, or baseline number of Gd? lesions, years
since diagnosis, and number of relapses in the previous 3
years as categorical variables. The odds ratio (OR) of
lesion evolution from Gd? to T1-hypointense was com-
puted using the placebo group as a reference.
Results
The 24 week, placebo-controlled period of the BG-12
phase 2b clinical study included 65 patients in the placebo
group and 63 patients in the BG-12 240 mg tid group. Of
these, twice as many patients in the placebo group (n = 38)
than in the BG-12 group (n =18) had one or more Gd?
lesion at weeks 4–12 and were included in the retrospective
analysis. The demographic and baseline patient character-
istics of the present study cohort were similar to those of
the entire study population (Table 1) [8]. At baseline, the
mean number of Gd? lesions was slightly higher in the
BG-12 group (3.3 in 18 patients) compared with placebo
(2.7 in 38 patients) (p = not significant). Because we
selected patients who had one or more Gd? lesions from
weeks 4 to 12, it was not surprising that the mean number
of baseline Gd? lesions in the present retrospective anal-
ysis cohort was slightly higher than that for the entire phase
2b study population in the placebo (2.7 in the present
analysis vs. 1.6 in the entire phase 2b study population) and
BG-12 (3.3 in the present analysis vs. 1.3 in the entire
phase 2b study population) groups.
When analyzing these data at the patient level (i.e.,
proportion of Gd? lesions that converted to T1-hypoin-
tense lesions was calculated for each patient and summary
statistics for both treatment groups were tallied), the 18
patients in the BG-12 group had a higher mean number of
Gd? lesions (8.2) than the 38 patients in the placebo group
(5.8) on scans at weeks 4, 8, and 12 (Table 2). However,
the mean number of T1-hypointense lesions formed from
the Gd? lesions by week 24 was similar in the BG-12 and
placebo groups (2.3, BG-12; 2.6, placebo) (p = not sig-
nificant). This result is due to the fact that the mean pro-
portion of Gd? lesions that evolved to T1-hypointense
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lesions per patient was 0.29 in the BG-12 group compared
with 0.41 in the placebo group; this outcome represents a
29% reduction in evolved Gd? lesions with BG-12 treat-
ment when analyzing lesions at the patient level.
When analyzing these data at the lesion level (i.e., each
lesion is counted as one observation in the analysis), 147
new Gd? lesions from the 18 patients in the BG-12 group
and 221 Gd? lesions from the 38 patients in the placebo
group were tracked on scans from weeks 4 through 12 and
analyzed at week 24 to see if they had evolved into a T1
hypointensity (Fig. 1; Table 2). The proportion of total
Gd? lesions that evolved to T1-hypointense lesions was
0.29 in the BG-12 group versus 0.44 in the placebo group
(Fig. 1; Table 2); this result represents a 34% reduction
when analyzing data at the lesion level with BG-12
treatment compared with placebo. The OR for the evolu-
tion of new Gd? lesions to T1-hypointense lesions for BG-
12 compared with placebo was 0.51 (95% confidence
interval [CI] 0.43, 0.61; p \ 0.0001). When the model was
adjusted for years since disease onset and relapses in the
previous 3 years in addition to baseline Gd? lesions, the
OR was 0.40 (95% CI 0.25, 0.66; p = 0.0003). Similarly,
when the model was adjusted for years since diagnosis and
relapses in the previous 3 years in addition to baseline Gd?
lesions, the OR was 0.49 (95% CI 0.27, 0.88; p = 0.0171).
Exclusion of three patients (two from the placebo group
and one from the BG-12 group) who had relatively large
numbers (C40) of Gd? lesions from the analysis did not
influence this result (OR 0.65; 95% CI 0.47, 0.89;
p = 0.008).
When analyzing these data by lesion size, 40 (27%) of
the Gd? lesions in the BG-12 group and 76 (34%) of the
Gd? lesions in the placebo group were classified as large
([5 mm) on the basis of lesion diameter (Fig. 1). In pla-
cebo-treated patients, the probability of large Gd? lesions
becoming T1 hypointense was higher than that for small
Gd? lesions (B5 mm) (48/76 [0.63] vs. 50/145 [0.34])
(Table 2). In BG-12-treated patients, large Gd? lesions
also were more likely to become T1 hypointense than were
small Gd? lesions (21/40 [0.52] vs. 21/107 [0.20]). There
was a trend for fewer large Gd? lesions to evolve to
T1-hypointense lesions in the BG-12 treatment arm com-
pared with placebo (OR 0.62; 95% CI 0.39, 1.01;
p = 0.055). The probability of small Gd? lesions evolving
to T1-hypointense lesions was significantly lower with
BG-12 treatment compared with placebo (OR 0.37; 95% CI
0.30, 0.45; p \ 0.0001). Overall, the proportion of large
T1-hypointense lesions that evolved from any Gd? lesions
(large or small) was not different in the BG-12-treated
group (10%) compared with the placebo group (15%)
(p = 0.251).
Discussion
In this retrospective analysis of a phase 2b study, treatment
with 240 mg BG-12 tid orally for 24 weeks reduced the
probability of evolution of new Gd? lesions to T1-hypo-
intense lesions compared with placebo in patients with
relapsing MS (OR 0.51; 95% CI 0.43, 0.61; p \ 0.0001).
Even when the model was adjusted for additional baseline
factors, including disease duration and relapse activity in
the previous 3 years, the difference between the BG-12 and
placebo groups remained significant (p = 0.0171).
A potential mechanism for reduced evolution from Gd?
to T1 hypointensity is a reduction in the size of Gd?
lesions because larger Gd? lesions are more likely to
become T1 hypointense (as seen in the placebo arm of the
Table 1 Demographic and baseline patient characteristics
Placebo (n =38) 240 mg BG-12 tid (n =18)
Age, years
Mean 34.9 33.4
Median 35.0 30.0
Range 21–49 18–51
Gender, n (%)
Male 14 (37) 7 (39)
Female 24 (63) 11 (61)
EDSS score
Mean 2.5 3.0
Range 0–5 1–5
Time since disease onset, years
Mean 8.0 8.5
Median 6.0 7.5
Range 1–28 1–23
Time since diagnosis, years
Mean 5.1 4.1
Median 4.0 3.0
Range 0–26 0–9
No. of relapses
Prior year
Mean 1.3 1.4
Median 1.0 1.0
Range 0–3 1–2
Prior 3 years
Mean 2.4 3.2
Median 2.0 3.0
Range 1–5 1–7
No. of Gd ? lesions at baseline
Mean 2.7 3.3
Median 1.0 1.0
Range 0–53 0–19
tid three times daily, EDSS Expanded Disability Status Scale, Gd?
gadolinium enhancing
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present study and in a previous study [13]). Although the
proportion of large Gd? lesions was slightly lower in BG-
12-treated versus placebo-treated patients (27 vs. 34%),
this mechanism does not explain the reduced conversion to
T1 hypointensity, which was evident for small and large
Gd? lesions, though more so for small lesions (63%
reduction in odds of lesion evolution for small Gd?
lesions [p \ 0.001] vs. 38% reduction for large lesions
[p = 0.055]).
The development of new Gd? lesions on T1-weighted
MRI indicates blood–brain barrier breakdown and sug-
gests active inflammation at the site of enhancement [15].
Most new Gd? lesions are hypointense on unenhanced
T1-weighted images during the acute phase, but many of
these lesions become T1 isointense during follow-up [9];
most remain visible as high-signal lesions on T2-weighted
images. Histopathological studies have shown that
persistent T1-hypointense lesions are less likely to
remyelinate [16] and are associated with greater tissue
matrix damage, including axonal loss, compared with
T1-isointense lesions [10, 17, 18]. Thus, therapeutic agents
that limit the evolution of new Gd? lesions to T1-hypo-
intense lesions are likely to confer benefit to patients with
MS by reducing the extent of axonal damage at the lesion
site. Similar to BG-12, some currently approved MS dis-
ease-modifying therapies affect the evolution of Gd?
lesions to T1-hypointense lesions [14, 19]. In patients
treated with natalizumab, the proportion of Gd? lesions
that evolved to T1-hypointense lesions was 15% (vs. 25%
in the placebo group, p = 0.045) and the OR of evolution
from Gd? to T1-hypointense lesions was 0.48 (95% CI
0.24, 0.94; p = 0.031) [14]. Glatiramer acetate has also
been shown to reduce the evolution of Gd? lesions to
T1-hypointense lesions compared with placebo (16% vs.
Table 2 Number of new Gd? lesions on scans from weeks 4 to 12 and number and proportion evolving to T1-hypointense lesions at week 24
Lesion level 
No. of T1-hypointense lesions on scan from week 24 
No. of Gd+ lesions on scans from weeks 4 to 12 
98
221
42
147
Proportion of Gd+ lesions evolved to T1-hypointense lesions at week 24 0.44 0.29
Odds ratio for probability of evolution from Gd+ lesions to T1-hypointense lesions 
(95% CI), BG-12 vs. placeboa
0.51 (0.43, 0.61) 
p < 0.0001 
   No. of T1-hypointense lesions on scan from week 24 
No. of large Gd+ lesions on scans from weeks 4 to 12 
48
76
21
40
Proportion of large Gd+ lesions evolved to T1-hypointense lesions at week 24  0.63 0.52
Odds ratio for probability of evolution from large Gd+ lesions to T1-hypointense 
lesions (95% CI), BG-12 vs. placeboa
0.62 (0.39, 1.01) 
p = 0.055 
   No. of T1-hypointense lesions on scan from week 24 
   No. of small Gd+ lesions on scans from weeks 4 to 12 
50
145
21
107
Proportion of small Gd+ lesions evolved to T1-hypointense lesions at week 24 0.34 0.20
Odds ratio for probability of evolution from small Gd+ lesions to T1-hypointense 
lesions (95% CI), BG-12 vs. placeboa
0.37 (0.30, 0.45) 
p < 0.0001 
Placebo
(n = 38)
240 mg BG-12 
tid (n = 18) 
Patient level
No. of new Gd+ lesions per patient on scans from weeks 4 to 12
Mean (SD)
Median
Range
5.80 (9.50)
3.0
1 45
8.20 (13.35)
4.0
1 59
No. of T1-hypointense lesions at week 24, n (%)
0
1
2
3
Mean (SD)
12 (32)
10 (26)
5 (13)
11 (29)
2.60 (4.91)
5 (28)
7 (39)
1 (6)
5 (28)
2.30 (3.97)
Proportion of Gd+ lesions per patient evolved to T1-hypointense lesions at week 24, mean (SD) 0.41 (0.37) 0.29 (0.30)
a Analysis was performed using a logistic regression model based on the generalized estimating equation which takes into account within-patient
correlation of the lesions, and adjusted for baseline number of Gd? lesions
Gd? gadolinium enhancing, tid three times daily, SD standard deviation, CI confidence interval
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31%, p = 0.002) [19]. Although one study showed no
such effect for interferon beta-1b versus placebo [13], a
recent study reported fewer Gd? lesions evolving to
T1-hypointense lesions with interferon beta-1b compared
with glatiramer acetate [20].
Anti-inflammatory effects of oral fumarates have been
demonstrated in preclinical and clinical studies [1, 21] and
were the initial reason for the development of BG-12 as a
therapeutic agent in MS [1]. BG-12 can activate the Nrf2
transcriptional pathway in cultured cells [3]. The Nrf2
pathway is known to be a critical regulator of oxidative and
metabolic stress response, and activation of this pathway
confers neuroprotective effects. Specifically, scientific
evidence suggests that Nrf2 mediates its protective effects
by increasing the transcription of genes coding for detox-
ification enzymes and improving neuronal survival
[22–24], maintaining the integrity of myelin [7], and pro-
tecting the blood–brain barrier [25].
A recent analysis evaluated the feasibility of using the
evolution of contrast-enhancing lesions to T1-hypointense
lesions as a marker of protection against subsequent axonal
loss of treatment. The authors concluded that 200 patients
per treatment arm would be required to detect a treatment
effect of 50% [26]. Given these results, our analysis may be
underpowered to detect a treatment effect; however, the
greater effect of 240 mg BG-12 tid on T1-hypointense
lesions compared with T2-hyperintense lesions observed in
the overall phase 2b study supports the results of the
present retrospective analysis and warrants further
investigation.
Taken together, the primary results from the phase 2b
study of BG-12 in patients with relapsing MS and the
results of the retrospective analysis presented here provide
evidence suggesting both an anti-inflammatory effect
(reduced number of Gd? lesions) and reduced axonal loss
in post-inflammatory lesions (fewer Gd? lesions becoming
T1-hypointense). The reduced evolution of T1-hypointense
lesions from Gd? lesions was observed over a relatively
short (i.e., 6 months) treatment period, and future longer-
term studies will help to better understand the significance
of these preliminary findings and their implications with
regard to protection from axonal damage.
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